Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Lung Neoplasms 2Lethal Congenital Contracture Syndrome 2 2Head and Neck Neoplasms 2Fibromatosis, Gingival, 2 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Cancers 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 281pembrolizumab 234Radiotherapy 171Cetuximab 169Carboplatin 123Docetaxel 110Paclitaxel 96Fluorouracil 95Nivolumab 88Radiotherapy, Intensity-Modulated 80Magnetic Resonance Spectroscopy 39durvalumab 36Radiation 33Surgical Procedures, Operative 32Drug Therapy 32Biopsy 28Radiosurgery 25Erlotinib Hydrochloride 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Specimen Handling 22Platinum 22Immunohistochemistry 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Chemoradiotherapy 19Capecitabine 19tremelimumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × seribantumab × Clear all
NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

Merrimack Pharmaceuticals

Phase 1 Terminated
5 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡